Patent: 9,815,894
✉ Email this page to a colleague
Summary for Patent: 9,815,894
Title: | Use of reslizumab to treat moderate to severe eosinophilic asthma |
Abstract: | Disclosed herein are methods of treating moderate to severe eosinophilic asthma in a patient comprising administering a therapeutically effective dose of reslizumab to a patient whose symptoms are inadequately controlled with a current asthma therapeutic and wherein the patient\'s blood eosinophil levels are equal to or greater than 400/.mu.L. |
Inventor(s): | O\'Brien; Christopher (Lafayette Hill, PA), Zangrilli; James (Philadelphia, PA), Shah; Tushar (Flemington, NJ) |
Assignee: | Cephalon, Inc. (Frazer, PA) |
Application Number: | 14/838,503 |
Patent Claims: | see list of patent claims |
Details for Patent 9,815,894
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Teva Respiratory, Llc | CINQAIR | reslizumab | Injection | 761033 | 03/23/2016 | ⤷ Try a Trial | 2034-09-08 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |